TY - JOUR
T1 - Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation in Japan
AU - Kida, Michiko
AU - Usuki, Kensuke
AU - Uchida, Naoyuki
AU - Fukuda, Takahiro
AU - Katayama, Yuta
AU - Kondo, Tadakazu
AU - Eto, Tetsuya
AU - Matsuoka, Ken ichi
AU - Matsuhashi, Yoshiko
AU - Ota, Shuichi
AU - Sawa, Masashi
AU - Miyamoto, Toshihiro
AU - Ichinohe, Tatsuo
AU - Kimura, Takafumi
AU - Atsuta, Yoshiko
AU - Takami, Akiyoshi
AU - Miyazaki, Yasushi
AU - Yano, Shingo
AU - Ishiyama, Ken
AU - Yanada, Masamitsu
AU - Aoki, Jun
N1 - Publisher Copyright:
© 2020 American Society for Transplantation and Cellular Therapy
PY - 2020/8
Y1 - 2020/8
N2 - This study aimed to investigate allogeneic hematopoietic cell transplantation (HCT) outcomes and risk factors in adult patients with therapy-related myeloid neoplasm (t-MN) using Japanese registry data. Between 2002 and 2012, a total 12,169 adult patients underwent HCT for acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML). Of these, 565 with t-MN were identified. The median patient age was 54 years (range, 16 to 80 years). Three hundred and ninety-eight patients had AML, 154 had MDS, and 13 had CMML. Lymphoma and breast cancer were the major previous malignancies. Favorable karyotypes were detected in 84 patients, and poor karyotypes were identified in 235. Two-thirds (66%) of the patients were in nonremission at HCT. Overall survival at 3 years in patients with t-MN was 31% (95% confidence interval [CI], 27% to 35%), equivalent to that in those with secondary MN (32%; 95% CI, 30% to 34%), and 44% in the de novo cohort (95% CI, 43% to 45%). The cumulative incidence of relapse and nonrelapse mortality at 3 years was 40% and 33%, respectively. The outcomes of HCT for t-MN in Japan were comparable to those in large-scale studies in Europe and the United States.
AB - This study aimed to investigate allogeneic hematopoietic cell transplantation (HCT) outcomes and risk factors in adult patients with therapy-related myeloid neoplasm (t-MN) using Japanese registry data. Between 2002 and 2012, a total 12,169 adult patients underwent HCT for acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML). Of these, 565 with t-MN were identified. The median patient age was 54 years (range, 16 to 80 years). Three hundred and ninety-eight patients had AML, 154 had MDS, and 13 had CMML. Lymphoma and breast cancer were the major previous malignancies. Favorable karyotypes were detected in 84 patients, and poor karyotypes were identified in 235. Two-thirds (66%) of the patients were in nonremission at HCT. Overall survival at 3 years in patients with t-MN was 31% (95% confidence interval [CI], 27% to 35%), equivalent to that in those with secondary MN (32%; 95% CI, 30% to 34%), and 44% in the de novo cohort (95% CI, 43% to 45%). The cumulative incidence of relapse and nonrelapse mortality at 3 years was 40% and 33%, respectively. The outcomes of HCT for t-MN in Japan were comparable to those in large-scale studies in Europe and the United States.
KW - Acute myelogenous leukemia
KW - Allogeneic stem cell transplantation
KW - Myelodysplastic syndrome
KW - Myelodysplastic syndrome/myeloproliferative neoplasm
KW - Therapy-related
UR - http://www.scopus.com/inward/record.url?scp=85085279669&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085279669&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2020.04.004
DO - 10.1016/j.bbmt.2020.04.004
M3 - Article
C2 - 32320746
AN - SCOPUS:85085279669
VL - 26
SP - 1543
EP - 1551
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
SN - 1083-8791
IS - 8
ER -
